Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCMDC-135051
- Development stage
- Preclinical
- Lead developer
- GSK
- Modality
- Small Molecules
01
Overview
TCMDC-135051 is a highly selective and potent small molecule inhibitor of the Plasmodium falciparum cyclin-dependent-like kinase 3 (PfCLK3), an essential protein kinase involved in RNA splicing and parasite survival. It acts as a reversible inhibitor with low off-target toxicity and demonstrates activity against multiple life stages of malaria parasites—including blood stage trophozoite-to-schizont transition, gametocyte development, and liver stage parasites. The compound has shown efficacy against both chloroquine-sensitive and resistant P. falciparum strains as well as other Plasmodium species. Its mechanism offers potential for curative treatment, transmission blocking, and prophylaxis in malaria[1][2][3][4][8].
- Other names
- TCMDC-135051 hydrochlorideTCMDC135051 hydrochlorideTCMDC 135051 hydrochlorideTCMDC-135051 (hydrochloride)HY-126323BHY126323BHY 126323BMS-29440MS29440MS 294402705545-47-5CHEMBL4798421CHEMBL-4798421CHEMBL 4798421PubChem CID 139035060
02
Targets
PfCLK3 (Plasmodium falciparum CDC-like kinase 3)
Beyond the preview
Go deeper on TCMDC-135051.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCMDC-135051.